Okyo Pharma Plans Underwritten Public Offering of Ordinary Shares
Okyo Pharma Limited announced that it intends to offer to sell its ordinary shares in an underwritten public offering. All of the ordinary shares are to be sold by the company. The company intends to use the net proceeds from the offering primarily for clinical development of its product candidates, general corporate purposes and working capital. Piper Sandler & Co. is acting as the sole book-running manager for the offering.
